LAG3
Lymphocyte activation gene 3 protein
Also known as: CD223, LAG3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P18627
- Gene
- LAG3
- Ensembl
- ENSG00000089692
- Chromosome
- 12
- Canonical length
- 525 aa
- Protein class
- CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins
- Secretome location
- Intracellular and membrane
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
525 residues, UniProt reviewed canonical sequence.
>P18627|LAG3
1 MWEAQFLGLL FLQPLWVAPV KPLQPGAEVP VVWAQEGAPA QLPCSPTIPL QDLSLLRRAG
61 VTWQHQPDSG PPAAAPGHPL APGPHPAAPS SWGPRPRRYT VLSVGPGGLR SGRLPLQPRV
121 QLDERGRQRG DFSLWLRPAR RADAGEYRAA VHLRDRALSC RLRLRLGQAS MTASPPGSLR
181 ASDWVILNCS FSRPDRPASV HWFRNRGQGR VPVRESPHHH LAESFLFLPQ VSPMDSGPWG
241 CILTYRDGFN VSIMYNLTVL GLEPPTPLTV YAGAGSRVGL PCRLPAGVGT RSFLTAKWTP
301 PGGGPDLLVT GDNGDFTLRL EDVSQAQAGT YTCHIHLQEQ QLNATVTLAI ITVTPKSFGS
361 PGSLGKLLCE VTPVSGQERF VWSSLDTPSQ RSFSGPWLEA QEAQLLSQPW QCQLYQGERL
421 LGAAVYFTEL SSPGAQRSGR APGALPAGHL LLFLILGVLS LLLLVTGAFG FHLWRRQWRP
481 RRFSALEQGI HPPQAQSKIE ELEQEPEPEP EPEPEPEPEP EPEQLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LAG3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 22 nTPM
Expression across tissuesHPA
Tissue
- spleen: 22 nTPM
- ovary: 18 nTPM
- lymph node: 15 nTPM
- choroid plexus: 13 nTPM
- tonsil: 10 nTPM
- endometrium: 7.2 nTPM
Single-cell type
- peritubular myoid cells: 69 nCPM
- t-cells: 55 nCPM
- leydig cells: 39 nCPM
- ovarian stromal cells: 28 nCPM
- hofbauer cells: 28 nCPM
- breast secretory cells: 25 nCPM
Immune cell
- gdT-cell: 13 nTPM
- memory CD8 T-cell: 11 nTPM
- MAIT T-cell: 10 nTPM
- naive CD8 T-cell: 4.2 nTPM
- memory CD4 T-cell: 2.4 nTPM
- T-reg: 2 nTPM
Brain region
- choroid plexus: 8.5 nTPM
- cerebral cortex: 1.1 nTPM
- spinal cord: 1 nTPM
- medulla oblongata: 0.9 nTPM
- pons: 0.6 nTPM
- white matter: 0.6 nTPM
ReferencesPubMed · IEDB
Publications for LAG3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
- Lymphocyte Activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity.
2014 · PLoS One · RCR 1 · 40 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.5
- gnomAD pLI
- 0.28
- gnomAD missense Z
- 0.51
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adaptive immune response
- cell surface receptor signaling pathway
- innate immune response
- natural killer cell mediated cytotoxicity
- negative regulation of interleukin-2 production
- negative regulation of regulatory T cell differentiation
- negative regulation of T cell activation
- negative regulation of T cell mediated immune response to tumor cell
- negative regulation of T cell receptor signaling pathway
- plasmacytoid dendritic cell activation
- positive regulation of natural killer cell mediated cytotoxicity
- regulation of immune response
- T cell activation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LAG3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LAG3 as an antibody target. Whether an autoantibody or antibody against LAG3 could matter depends on whether native LAG3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LAG3 is annotated at the cell surface, where native LAG3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LAG3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...